Everything below concerns Plasma half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
=== 2000–2006 === The years from 2000 to 2006 were bloody ones in Colombia with thousands of deaths every year resulting from the ongoing war between the Colombian Armed Forces, Paramilitary groups such as the AUC, and the rebel groups (mainly the FARC, ELN and the EPL). The fighting resulted in massive internal displacement of Colombia's civilian population and thousands of civilian deaths. During President Uribe's first term in office (2002–2006), the security situation inside Colombia showed some measure of improvement, and the economy, while still fragile, showed some positive signs of recovery, according to observers. However, relatively little had been accomplished in structurally solving the country's other grave problems, such as poverty and inequality, possibly in part due to legislative and political conflicts between the administration and the Colombian Congress (including those over a controversial project to eventually give Uribe the possibility of re-election) and a relative lack of freely allocated funds and credits. Some critical observers considered that Uribe's policies, while reducing crime and guerrilla activity, were too slanted in favor of a military solution to Colombia's internal war, while neglecting grave social and human rights concerns. Critics asked for Uribe's government to change this position and make serious efforts towards improving the human rights situation inside the country, protecting civilians, and reducing any abuses committed by the armed forces.
By the early 1990s, Roche Biomedical became one of the largest clinical laboratory networks in the United States, with 20 major laboratories and US$600 million in sales. Roche has also produced various HIV tests and antiretroviral drugs. It bought the patents for the polymerase chain reaction (PCR) technique in 1992. In 1995, the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman LaRoche's HIV protease inhibitor, saquinavir. Within 2 years of its approval (and that of ritonavir 4 months later) annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000. On 28 April 1995, Hoffmann-La Roche sold Roche Biomedical Laboratories, Inc. to National Health Laboratories Holdings Inc. (which then changed its name to Laboratory Corporation of America Holdings). Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002. In 1998, Roche acquired Corange Ltd, the parent company of Boehringer Mannheim and DePuy Manufacturing for $11 billion. Boehringer Mannheim would be rebranded as Roche Diagnostics and DePuy was sold to Johnson & Johnson. Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead tiered royalties of 14–22% of annual net sales without adjusting the payments for manufacturing costs, as had been allowed in the original licensing agreement.
Harbury and Halpin developed DNA template libraries that direct like genes the synthesis of DNA encoded organic libraries. The members of the template combinatorial library contain the codes of all BBs and their order of couplings. The figure shows one member of a simple ssDNA template library (A) containing the codes of three BBs (2, 4, 6) that planned to be successively attached. The coding regions are separated by the same non-coding regions (1, 3, 5, 7) in all members. The sequence directed procedure uses a series of columns of resin beads each coated with the anticodon of one of the BBs (B). When the template library is transferred to an anticodon column the proper template member is captured by hybridization then is coupled with the appropriate BB. After finished with all anticodon columns of a coupling position (CP) the libraries are eluted from the beads of the anticodon columns mixed and the mentioned operations are repeated with the series of anticodon columns of the next CP. In figure, C shows one member of the template library captured by the “yellow” second CP anticodon library. The template contains the “red” BB already coupled in CP1 and the “yellow” BB attached after its capture. The final library contains all of the synthesized organic compounds attached to their encoding DNA oligomers.
The IFAW found that up to 90% of the elephant-ivory transactions on eBay violated their own wildlife policies and could potentially be illegal. In October 2008, eBay expanded the ban, disallowing any sales of ivory on eBay. A more recent sale in 2008 of 108 tonnes from the three countries and South Africa took place to Japan and China. The inclusion of China as an "approved" importing country created enormous controversy, despite being supported by CITES, the World Wide Fund for Nature and Traffic. They argued that China had controls in place and the sale might depress prices. However, the price of ivory in China has skyrocketed. Some believe this may be due to deliberate price fixing by those who bought the stockpile, echoing the warnings from the Japan Wildlife Conservation Society on price-fixing after sales to Japan in 1997, and monopoly given to traders who bought stockpiles from Burundi and Singapore in the 1980s. A 2019 peer-reviewed study reported that the rate of African elephant poaching was in decline, with the annual poaching mortality rate peaking at over 10% in 2011 and falling to below 4% by 2017. The study found that the "annual poaching rates in 53 sites strongly correlate with proxies of ivory demand in the main Chinese markets, whereas between-country and between-site variation is strongly associated with indicators of corruption and poverty." Based on these findings, the study authors recommended action to both reduce demand for ivory in China and other main markets and to decrease corruption and poverty in Africa.
== Mechanism == The main function of the SEC23A protein is to hydrolyze or break down a guanosine triphosphate (GTP) molecule bound to the SAR1A protein at the start of the COPII pathway. The energy released from the breaking of the GTP bond provides energy necessary to undergo another reaction. This triggers uncoating of the vesicle (a membrane bound carrying compartment for molecules) containing a secretory protein destined for packaging in the Golgi apparatus of the cell. Uncoating the vesicle exposes SNARE proteins which are needed for the vesicle to bind to the membrane site on the endoplasmic reticulum. A mutation in the SEC23A gene prevents the vesicle from uncoating so it will not bind to the receptor site on the endoplasmic reticulum to be released into the cytoplasm for transport to the Golgi apparatus. Thus, the vesicles will accumulate in the endoplasmic reticulum, causing it to become enlarged or distended. Ultimately, this causes the craniofacial symptoms present in patients with CLSD. This is probably due to abnormal secretion of collagen and possibly other secretory proteins which have accumulated in the endoplasmic reticulum. Collagen is responsible to for skull ossification, among other things.
Sources: en.wikipedia.org
== History == In 1863, German chemists Ferdinand Reich and Hieronymus Theodor Richter were testing ores from the mines around Freiberg, Saxony. They dissolved the minerals pyrite, arsenopyrite, galena and sphalerite in hydrochloric acid and distilled raw zinc chloride. Reich, who was color-blind, employed Richter as an assistant for detecting the colored spectral lines. Knowing that ores from that region sometimes contain thallium, they searched for the green thallium emission spectrum lines. Instead, they found a bright blue line. Because that blue line did not match any known element, they hypothesized a new element was present in the minerals. They named the element indium, from the indigo color seen in its spectrum, after the Latin indicum, meaning 'of India'. Richter went on to isolate the metal in 1864. An ingot of 0.5 kg (1.1 lb) was presented at the World Fair 1867. Reich and Richter later fell out when Richter claimed to be the sole discoverer.
=== Outcome and management === The liver injury due to the carbapenems is usually mild and self-limited. Rarely, the carbapenems can cause a clinically apparent acute cholestatic hepatitis that is usually self-limiting and not requiring therapy or intervention. In patients with vanishing bile duct syndrome, corticosteroids are often used but have not been shown to be beneficial and are best avoided. Some patients may benefit from symptomatic therapy of the pruritus associated with cholestasis using antihistamines, ursodiol, or cholestyramine. Little information is available on possible cross-sensitivity to liver injury among the different betalactam antibiotics, but patients with clinically apparent liver injury due to imipenem should probably avoid the other carbapenems.
In 1942, the Nationalists conducted a major fiscal reorganization by abolishing provincial budgets and centralizing financial control, a move that ironically led to many local administrations relying even less on the central government because they had lost funding. These local administrations were forced to turn to other measures to support themselves. Liu Wenhui, who had already been involved in the opium trade prior to 1942, now faced the loss of his stipend from both the central government and the Sichuanese provincial government. Liu's budgetary situation had already been precarious: in 1939, Xikang's expenditures were around 5.4 million yuan, but non-opium income only amounted to 1.4 million yuan. Liu began growing opium on a systematic scale around the early 1940s. He instituted taxes on opium, taxes for not growing opium (the "laziness tax"), taxes on the import, export, and sale of opium, and "red light" taxes on opium dens. After 1942, each county in Xikang was assigned an annual tax quota of at least 100 dan (160,000 liang), with total revenues estimated at at least 3-4,000 dan. The price per liang of opium was one to two silver dollars in Xikang and three to four dollars in the Sichuan basin, not counting shortages. During the communist era, when opium consumption was strictly prohibited, Liu admitted that his strategy was one of "drinking poison to quench thirst." However, he blamed Chiang Kai-shek for forcing him into a situation where he had no other choice but to cultivate, trade, and tax opium.
=== Burns === The Healing Foundation facilitated the establishment of two research centres dedicated to burns. The first, situated at Frenchay Hospital in Bristol, aimed to develop innovative techniques for burn prevention and enhance clinical care for affected children. The Centre for Children's Burns Research was officially opened in June 2013 by Sophie, Duchess of Edinburgh. Subsequently, another research hub, the Healing Foundation Centre for Burns Research, was inaugurated at Queen Elizabeth Hospital in Birmingham in October 2013. A notable outcome of The Healing Foundation Centre for Children's Burns Research was the SmartWound PREDICT Dressing, developed by scientists at the University of Bath. This dressing changes colour upon detecting bacteria, providing an alternative method for infection detection.
Sources: en.wikipedia.org
The Administrative and Program Enrichment Core coordinates Center activities, provides biostatistical support, promotes community engagement, and facilitates career development through seminars, workshops, and the internationally recognized Masoro-Barshop Conference on Aging. The Aging Animal and Functional Assessment Core offers access to aged animal colonies, longevity studies, and comprehensive assessments of physical and physiological function. The GeroMetabolism Core provides advanced metabolomic, lipidomic, and metabolic phenotyping capabilities that enable investigators to examine metabolic mechanisms underlying aging and age-related diseases. The Pathology Core delivers expert histopathologic evaluation and disease phenotyping across multiple organ systems, while the Pharmacology and Drug Design Core supports the identification, optimization, and evaluation of pharmacological interventions targeting aging pathways. Finally, the Research Development Core expands aging research by providing pilot funding, mentorship, trainee support, and access to Center resources for investigators both within UT Health San Antonio and across the United States. A distinguishing strength of the San Antonio Nathan Shock Center is its commitment to developing the next generation of geroscientists. Through pilot grant programs, mentorship initiatives, trainee internships, educational workshops, and collaborative research opportunities, the Center provides critical support for early-stage investigators pursuing careers in aging research.
Additionally, they were able to tune the retention factor for the analytes through isocratic temperature gradient elution. Ideal elutions occurred at 35 °C, but decreasing the temperature to 10 °C or raising it to 50 °C caused faster elutions either way. This is a strong indication that electrostatic and hydrophobic interactions can be similarly affected by changes in temperature. The major advantages from applying these success of this study include stationary phase versatility and maintaining bioactivity of the analytes. Ayano et al. modified PNIPAAm with cationic N,N-dimethylaminopropylacrylamide (DMAPAAm) and hydrophobic BMA and grafted it onto silica beads to form IDB. They used pH changes to adjust the LCST. The effect of pH on the LCST is as follows, from a plateau value between pH 4.5 and pH 6.0, the LCST decreased up to pH 9 and below pH 4.5. This can be interpreted as requiring slightly basic or moderately acidic conditions, as the 4.5–6.0 pH region holds a maximum value of the LCST, an unfavorable condition. They used these properties to separate several non-steroidal anti-inflammatory drugs (NSAIDs). The analysis of acidic drugs (salicylic acid: BA; SA; MS; and As) was performed below pH 4.5. MS is hydrophobic only its retention time was affected by an increase in temperature on the column without a terminally modified anion-exchanger (IB column). However, with an anion-exchanger present, dissociated acidic drugs were retained longer at temperatures below LCST, and shorter at temperatures above LCST.
In testimony before the US Senate Foreign Relations Committee on 28 January, US Secretary of State Marco Rubio did not confirm the story when asked by Senator Jeanne Shaheen and instead only noted that Rodríguez had not been indicted, saying: "We are dealing with individuals that in our system would not be acceptable in the long term. But we are in a transition to stabilization phase. You have to work with the people currently in charge of the elements of government."
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.